Table 3

Adverse events occurring in at least 10% of patients in either treatment group.

Adverse event

Sugammadex (n = 46)

Neostigmine (n = 36)


Procedural pain

33 (71.7)

24 (66.7)

Nausea

24 (52.2)

12 (33.3)

Incision-site complication

10 (21.7)

8 (22.2)

Pharyngolaryngeal pain

8 (17.4)

7 (19.4)

Headache

12 (26.1)

2 (5.6)

Vomiting

9 (19.6)

4 (11.1)

Dizziness

5 (10.9)

4 (11.1)

Pruritus

5 (10.9)

2 (5.6)

Post-procedural nausea

5 (10.9)

2 (5.6)

Constipation

5 (10.9)

0

Chills

5 (10.9)

0


Adverse events are listed regardless of their perceived relationship to study drug for the all-subjects-treated population (n = 82).

Lemmens et al. BMC Anesthesiology 2010 10:15   doi:10.1186/1471-2253-10-15

Open Data